Top

Published in:

01-03-2006 | Original Paper

Abundant hypermethylation of SOCS-1 in clinically silent pituitary adenomas

Authors: Rolf Buslei, Jürgen Kreutzer, Bernd Hofmann, Verena Schmidt, Florian Siebzehnrübl, Eric Hahnen, Ilker Y. Eyupoglu, Rudolf Fahlbusch, Ingmar Blümcke

Published in: Acta Neuropathologica | Issue 3/2006

Abstract

Janus kinase (JAK)/signal transducers and activators of transcription (STAT) cascade are required for cytokines, growth factors, G-proteins and hormones (growth hormone and prolactin). Gatekeepers in this pathway are the suppressor of cytokine signalling (SOCS) family of proteins. Their expression level is epigenetically regulated by DNA methylation. We have investigated the CpG island methylation status of SOCS-1 in a cohort of pituitary adenomas (PA; n=57), craniopharyngiomas (CP; n=30) and normal pituitary tissue (NP; n=11) using methylation sensitive single-strand conformation polymorphism analysis (MS-SSCP) and direct sequencing. SOCS-1 hypermethylation was identified in 51% (29/57) of surgical specimens obtained from PA patients. 83% of these tumours were clinically silent. In contrast, no methylation of SOCS-1 was observed in CPs or NPs. Quantitative real-time PCR and western blot analysis confirmed reduced SOCS-1 expression in the majority of pituitary adenomas. The data is compatible with epigenetic silencing of the SOCS-1 gene and constitutive activation of the JAK-STAT pathway in PA. This appears to contribute particularly to those tumours characterized by a hormone-inactive status.

Arzt E, Buric R, Stelzer G, Stalla J, Sauer J, Renner U, Stalla GK (1993) Interleukin involvement in anterior pituitary cell growth regulation: effects of IL-2 and IL-6. Endocrinology 132:459–467CrossRefPubMed

Auernhammer CJ, Bousquet C, Chesnokova V, Melmed S (2000) SOCS proteins: modulators of neuroimmunoendocrine functions. Impact on corticotroph LIF signaling. Ann N Y Acad Sci 917:658–664PubMedCrossRef

Auernhammer CJ, Melmed S (2001) The central role of SOCS-3 in integrating the neuro-immunoendocrine interface. J Clin Invest 108:1735–1740CrossRefPubMed

Bahar A, Bicknell JE, Simpson DJ, Clayton RN, Farrell WE (2004) Loss of expression of the growth inhibitory gene GADD45gamma, in human pituitary adenomas, is associated with CpG island methylation. Oncogene 23:936–944CrossRefPubMed

Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM (2003) Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63:1270–1279PubMed

Boudny V, Kovarik J (2002) JAK/STAT signaling pathways and cancer. Janus kinases/signal transducers and activators of transcription. Neoplasma 49:349–355PubMed

Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8:945–954PubMed

Buslei R, Nolde M, Hofmann B, Meissner S, Eyupoglu IY, Siebzehnrubl F, Hahnen E, Kreutzer J, Fahlbusch R (2005) Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol (Berl) 109:589–597CrossRef

Chesnokova V, Melmed S (2002) Minireview: neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. Endocrinology 143:1571–1574CrossRefPubMed

10.

Cooney RN (2002) Suppressors of cytokine signaling (SOCS): inhibitors of the JAK/STAT pathway. Shock 17:83–90CrossRefPubMed

11.

Dahia PL, Aguiar RC, Honegger J, Fahlbush R, Jordan S, Lowe DG, Lu X, Clayton RN, Besser GM, Grossman AB (1998) Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. Oncogene 16:69–76CrossRefPubMed

12.

Dobrovic A, Bianco T, Tan LW, Sanders T, Hussey D (2002) Screening for and analysis of methylation differences using methylation-sensitive single-strand conformation analysis. Methods 27:134–138CrossRefPubMed

13.

Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A (1997) A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387:921–924CrossRefPubMed

14.

Fahlbusch R, Honegger J, Paulus W, Huk W, Buchfelder M (1999) Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg 90:237–250PubMedCrossRef

15.

Farrell WE, Clayton RN (2003) Epigenetic change in pituitary tumorigenesis. Endocr Relat Cancer 10:323–330CrossRefPubMed

16.

Fujimoto M, Naka T (2003) Regulation of cytokine signaling by SOCS family molecules. Trends Immunol 24:659–666CrossRefPubMed

17.

Galm O, Herman G (2003) CpG island methylation: location matters. Blood 102:1554–1555CrossRefPubMed

18.

Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG (2003) SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101:2784–2788CrossRefPubMed

19.

Greenhalgh CJ, Rico-Bautista E, Lorentzon M, Thaus AL, Morgan PO, Willson TA, Zervoudakis P, Metcalf D, Street I, Nicola NA, Nash AD, Fabri LJ, Norstedt G, Ohlsson C, Flores-Morales A, Alexander WS, Hilton DJ (2005) SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest 115:397–406CrossRefPubMed

20.

Herman V, Drazin NZ, Gonsky R, Melmed S (1993) Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab 77:50–55CrossRefPubMed

21.

Ihle JN (1995) Cytokine receptor signalling. Nature 377:591–594CrossRefPubMed

22.

Ihle JN (1996) Janus kinases in cytokine signalling. Philos Trans R Soc Lond B Biol Sci 351:159–166PubMedCrossRef

23.

Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y, Sekikawa A, Kawada M, Suzuki K, Kayahara T, Fukui H, Sawada M, Chiba T (2004) STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 23:4921–4929CrossRefPubMed

24.

Karga HJ, Alexander JM, Hedley-Whyte ET, Klibanski A, Jameson JL (1992) Ras mutations in human pituitary tumors. J Clin Endocrinol Metab 74:914–919CrossRefPubMed

25.

Kramer JA, Adams MD, Singh GB, Doggett NA, Krawetz SA (1998) Extended analysis of the region encompassing the PRM1–>PRM2–>TNP2 domain: genomic organization, evolution and gene identification. J Exp Zool 282:245–253CrossRefPubMed

26.

Krebs DL, Hilton DJ (2000) SOCS: physiological suppressors of cytokine signaling. J Cell Sci 113(16):2813–2819PubMed

27.

Liu KD, Gaffen SL, Goldsmith MA (1998) JAK/STAT signaling by cytokine receptors. Curr Opin Immunol 10:271–278CrossRefPubMed

28.

McCabe CJ, Gittoes NJ (1999) PTTG–a new pituitary tumour transforming gene. J Endocrinol 162:163–166CrossRefPubMed

29.

Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, Jove R (2002) Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62:6659–6666PubMed

30.

Nagai H, Naka T, Terada Y, Komazaki T, Yabe A, Jin E, Kawanami O, Kishimoto T, Konishi N, Nakamura M, Kobayashi Y, Emi M (2003) Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas. J Hum Genet 48:65–69CrossRefPubMed

31.

Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, Akira S, Kishimoto T (1997) Structure and function of a new STAT-induced STAT inhibitor. Nature 387:924–929CrossRefPubMed

32.

Newell-Price J, King P, Clark AJ (2001) The CpG island promoter of the human proopiomelanocortin gene is methylated in nonexpressing normal tissue and tumors and represses expression. Mol Endocrinol 15:338–348CrossRefPubMed

33.

Okochi O, Hibi K, Sakai M, Inoue S, Takeda S, Kaneko T, Nakao A (2003) Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin Cancer Res 9:5295–5298PubMed

34.

Oshimo Y, Kuraoka K, Nakayama H, Kitadai Y, Yoshida K, Chayama K, Yasui W (2004) Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int J Cancer 112:1003–1009CrossRefPubMed

35.

Qian ZR, Sano T, Yoshimoto K, Yamada S, Ishizuka A, Mizusawa N, Horiguchi H, Hirokawa M, Asa SL (2005) Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas. Lab Invest 85:464–473CrossRefPubMed

36.

Quan N, Herkenham M (2002) Connecting cytokines and brain: a review of current issues. Histol Histopathol 17:273–288PubMed

37.

Rottapel R, Ilangumaran S, Neale C, La Rose J, Ho JM, Nguyen MH, Barber D, Dubreuil P, de Sepulveda P (2002) The tumor suppressor activity of SOCS-1. Oncogene 21:4351–4362CrossRefPubMed

38.

Ruebel KH, Jin L, Qian X, Scheithauer BW, Kovacs K, Nakamura N, Zhang H, Raz A, Lloyd RV (2005) Effects of DNA methylation on galectin-3 expression in pituitary tumors. Cancer Res 65:1136–1140CrossRefPubMed

39.

Sano T, Rong QZ, Kagawa N, Yamada S (2004) Down-regulation of E-cadherin and catenins in human pituitary growth hormone-producing adenomas. Front Horm Res 32:127–132PubMed

40.

Sekine S, Shibata T, Kokubu A, Morishita Y, Noguchi M, Nakanishi Y, Sakamoto M, Hirohashi S (2002) Craniopharyngiomas of adamantinomatous type harbor beta-catenin gene mutations. Am J Pathol 161:1997–2001PubMed

41.

Sekine S, Takata T, Shibata T, Mori M, Morishita Y, Noguchi M, Uchida T, Kanai Y, Hirohashi S (2004) Expression of enamel proteins and LEF1 in adamantinomatous craniopharyngioma: evidence for its odontogenic epithelial differentiation. Histopathology 45:573–579CrossRefPubMed

42.

Shimon I, Yan X, Ray DW, Melmed S (1997) Cytokine-dependent gp130 receptor subunit regulates human fetal pituitary adrenocorticotropin hormone and growth hormone secretion. J Clin Invest 100:357–363PubMed

43.

Simpson DJ, Bicknell JE, McNicol AM, Clayton RN, Farrell WE (1999) Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas. Genes Chromosomes Cancer 24:328–336CrossRefPubMed

44.

Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE (2000) Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 60:1211–1216PubMed

45.

Starr R, Hilton DJ (1998) SOCS: suppressors of cytokine signalling. Int J Biochem Cell Biol 30:1081–1085CrossRefPubMed

46.

Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387:917–921CrossRefPubMed

47.

Sutherland KD, Lindeman GJ, Choong DY, Wittlin S, Brentzell L, Phillips W, Campbell IG, Visvader JE (2004) Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 23:7726–7733CrossRefPubMed

48.

Thapar K, Kovacs K (1998) Neoplasms of the sellar region. In: Russell and Rubinstein´s Pathology of Tumors of the Nervous System, edn 6, pp 629–680

49.

Thiele JO, Lohrer P, Schaaf L, Feirer M, Stummer W, Losa M, Lange M, Tichomirowa M, Arzt E, Stalla GK, Renner U (2003) Functional in vitro studies on the role and regulation of interleukin-6 in human somatotroph pituitary adenomas. Eur J Endocrinol 149:455–461CrossRefPubMed

50.

Vallar L, Spada A, Giannattasio G (1987) Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 330:566–568CrossRefPubMed

51.

Wang J, Campbell IL (2002) Cytokine signaling in the brain: putting a SOCS in it? J Neurosci Res 67:423–427CrossRefPubMed

52.

Watanabe D, Ezoe S, Fujimoto M, Kimura A, Saito Y, Nagai H, Tachibana I, Matsumura I, Tanaka T, Kanegane H, Miyawaki T, Emi M, Kanakura Y, Kawase I, Naka T, Kishimoto T (2004) Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br J Haematol 126:726–735CrossRefPubMed

53.

Watanabe D, Naka T, Kishimoto T (2004) Implication of SOCS-1 gene methylation in acute myeloid leukaemia. Br J Haematol 127:608–609CrossRefPubMed

54.

Woloschak M, Yu A, Post KD (1997) Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation. Mol Carcinog 19:221–224CrossRefPubMed

55.

Wormald S, Hilton DJ (2004) Inhibitors of cytokine signal transduction. J Biol Chem 279:821–824CrossRefPubMed

56.

Yamashita H, Iwase H, Toyama T, Fujii Y (2003) Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells. Oncogene 22:1638–1652CrossRefPubMed

57.

Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG (2001) SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28:29–35CrossRefPubMed

58.

Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S (1999) Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84:761–767CrossRefPubMed

Title: Abundant hypermethylation of SOCS-1 in clinically silent pituitary adenomas
Authors: Rolf Buslei
Jürgen Kreutzer
Bernd Hofmann
Verena Schmidt
Florian Siebzehnrübl
Eric Hahnen
Ilker Y. Eyupoglu
Rudolf Fahlbusch
Ingmar Blümcke
Publication date: 01-03-2006
Publisher: Springer-Verlag
Published in: Acta Neuropathologica / Issue 3/2006
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-005-0009-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abundant hypermethylation of SOCS-1 in clinically silent pituitary adenomas

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2006

Expression of doublecortin in tumours of the central and peripheral nervous system and in human non-neuronal tissues

Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors

Intracellular calcium-binding protein S100A4 influences injury-induced migration of white matter astrocytes

Rare mutation of PIK3CA in meningiomas

Upregulation of type I interleukin−1 receptor after traumatic spinal cord injury in adult rats

Immunohistochemical expression of nestin in the non-tumorous hypophysis and in pituitary neoplasms